Mantle cell lymphoma: standards and therapeutic news

被引：1

作者：

Le Calloch, Ronan ^{[1
]}

Voldoire, Maud ^{[2
]}

Le Gouill, Steven ^{[2
]}

机构：

[1] CHRU Brest, Inst Canc Hematol, Serv Hematol Clin, Brest, France

[2] CHU Nantes, Serv Hematol Clin, UMR892, Nantes, France

来源：

HEMATOLOGIE | 2015年 / 21卷 / 03期

关键词：

mantle cell lymphoma;

D O I：

10.1684/hma.2015.1021

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Mantle cell lymphoma (MCL) is a rare and agressive form of non Hodgkin's lymphoma with one of the worst outcomes. The last decades have established a standard treatment based on the use of cytarabine combined with rituximab followed by a therapeutic intensification and autologous transplantation in young patients. Despite this, LCM remains an aggressive entity with many relapses. Currently, a new era is emerging with the development of new targeted therapies that are coming to change our attitudes and therefore the prognosis of this disease. This review presents the current standard treatment and therapeutic developments in MCL.

引用

页码：169 / 176

页数：8

共 50 条

[21] The current therapeutic scenario for relapsed mantle cell lymphoma
Ferrero, Simone
Dreyling, Martin
CURRENT OPINION IN ONCOLOGY, 2013, 25 (05) : 452 - 462
[22] Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
Vallumsetla, Nishanth
Paludo, Jonas
Kapoor, Prashant
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 1663 - 1674
[23] Mantle cell lymphoma: established therapeutic options and future directions
G. Lenz
M. Dreyling
W. Hiddemann
Annals of Hematology, 2004, 83 : 71 - 77
[24] Targeting the proteasome in mantle cell lymphoma: A promising therapeutic approach
Bogner, C
Peschel, C
Decker, T
LEUKEMIA & LYMPHOMA, 2006, 47 (02) : 195 - 205
[25] Mantle cell lymphoma: Therapeutic strategies are different from CLL
Wolfgang Hiddemann
Martin Dreyling
Current Treatment Options in Oncology, 2003, 4 (3) : 219 - 226
[26] Mantle cell lymphoma: established therapeutic options and future directions
Lenz, G
Dreyling, M
Hiddemann, W
ANNALS OF HEMATOLOGY, 2004, 83 (02) : 71 - 77
[27] The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma
Kumar, Sumukh Arun
Gao, Jenny
Patel, Shyam A.
LEUKEMIA RESEARCH, 2023, 134
[28] Mantle cell lymphoma: insights into therapeutic targets at the preclinical level
Klener, Pavel
EXPERT OPINION ON THERAPEUTIC TARGETS, 2020, 24 (10) : 1029 - 1045
[29] Properties of the mantle cell and mantle cell lymphoma
Frater, JL
Hsi, ED
CURRENT OPINION IN HEMATOLOGY, 2002, 9 (01) : 56 - 62
[30] News and therapeutic perspectives on cutaneous t-cell lymphoma
Battistella, Maxime
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2011, 138 : 19 - 22

← 1 2 3 4 5 →